Sydney, Australia 8 November 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that site activation at the Children’s Hospital at Westmead in Sydney has been completed and recruitment has commenced for its SARTATE™ Kids trial. Clarity’s SARTATE™ Kids trial is a Positron Emission Tomography (PET)…
Clarity Pharmaceuticals’ partner, the Idaho Accelerator Center at Idaho State University, was awarded the Early Stage Innovation of the Year at the 2017 Idaho Innovation Awards. This achievement was for the development of a new and efficient process for producing copper-67. This process enables copper-67 to be manufactured in sufficient quantities and at a high quality…
Sydney, Australia 31 October 2017 – Clarity Pharmaceuticals, an Australian radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that Professor Richard Wahl has joined their scientific advisory group. Richard Wahl, M.D., is the Elizabeth Mallinckrodt Professor, Chairman of the Department of Radiology and Director of the Mallinckrodt Institute of Radiology…
Sydney, Australia 15 August 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has been granted Ethics Approval by The Children’s Hospital at Westmead for its SARTATE™ Kids clinical trial for neuroblastoma. Clarity filed its ethics submission to the Sydney Children’s Hospital Network Human…
Sydney, Australia 4 July 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Dr Kathleen Miller, a US based experienced business development executive, to Clarity’s team. Dr Miller has over 25 years of experience in the pharmaceutical, medical imaging, and medical device industries,…
Sydney, Australia, 29 June 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has raised AU$4 million to develop its clinical pipeline using its proprietary theranostic technology and expand its presence in Europe and the US. The investment round includes strong support from current shareholders and a small number of…
Sydney, Australia 9 June 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the presentation of their poster at the upcoming 2017 Annual Meeting of Society for Nuclear Medicine and Medical Imaging (SNMMI) in Denver. Clarity’s Head of Quality, Dr Colin Biggin (also with RNT consulting),…
Clarity Pharmaceuticals was featured in Nature’s MedTech Dealmakers, a publication dedicated to exploring the dealmaking trends of the growing medical technology industry. The article discussed Clarity’s most recent developments and highlighted the benefits of using the Copper-64/Copper-67 pairing in the area of personalised medicine. Read the full article here: https://biopharmadealmakers.nature.com/users/37997-clarity-pharmaceuticals/documents/16507-clarity-pharmaceuticals-medtech-2017 Or as a PDF http://www.claritypharmaceuticals.com/wp-content/uploads/2017/05/Clarity-Pharmaceuticals-MedTech-2017.pdf…
Clarity Pharmaceuticals was featured in Biotech Dispatch, a publication dedicated to breaking news and commentary on the Australian biotechnology and life sciences sector. The article highlighted Clarity’s expansion to Europe through the establishment of a subsidiary Company in Liège, Belgium, and the awarding of a local grant. Read the full article here: http://biotechdispatch.com.au/clarity-establishes-european-subsidiary/#sthash.vlRgoIh5.VDwTViUT.dpbs Or as…
Sydney, Australia 19 January 2017 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Dr Colin Biggin as Head of Quality at Clarity. Dr Biggin has over 15 years’ experience in radiochemistry and radiopharmaceutical development. His most recent full-time role was with Algeta…